Skip to content
Review

Advances in diagnosis and treatment of angioimmunoblastic T-cell lymphoma.

Oct 2026 · Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis · Vol 171, pp. 108334 · 0 citations · 57 references
Medicine

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma (PTCL) that originates from follicular helper T cells (Tfh) and represents a rare subtype of non-Hodgkin lymphoma (NHL). The disease is characterized by unique morphological, molecular, and clinical features, and exhibits aggressive behavior. Currently, there is no standard treatment protocol, and patients treated with first-line CHOP-like chemotherapy show low remission rates, high recurrence rates, and poor overall prognosis. In recent years, with the in-depth study of the molecular genetic mechanism of AITL, various novel therapies have shown potential in patients with relapsed/refractory (R/R) AITL. This review aims to summarize the latest developments in the molecular mechanisms and treatment strategies of AITL, with the goal of providing references for clinical practice.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.